Table 8 Crude and adjusted Cox regression models evaluating the effect of treatment cessation in relation to laboratory confirmed SARS-CoV-2 infection or outpatient visits/inpatient hospitalizations with or without the need for ICU admission (i.e., restricting the analyses among those with ongoing treatment as opposed to ever treatment)
Laboratory confirmed SARS-CoV-2 | Outpatient visits/inpatient hospitalizations with/without ICU admission | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exposed | Unexposed | Exposed | Unexposed | |||||||||
Exposure | Person time (in years) | n events (%) | Person time (in years) | n events (%) | Crude HR (95% CI) | Adjusted HR (95% CI) | Person time (in years) | n events (%) | Person time (in years) | n events (%) | Crude HR (95% CI) | Adjusted HR (95% CI) |
Local estrogens alone | 3962 | 192 | 19,814 | 513 | 1.51 (1.28–1.78) | 1.50 (1.26–1.75 | 3962 | 135 | 19,812 | 510 | 1.07 (0.89–1.30) | 1.12 (0.93–1.36) |
Systemic estrogens without progestogens | 1238 | 128 | 6201 | 130 | 0.91 (0.71–1.16) | 0.93 (0.73–1.19) | 1242 | 45 | 6201 | 21 | 1.97 (1.17–3.30) | 1.99 (1.18–3.35) |
Estrogens and progestogens | 3247 | 365 | 16,252 | 794 | 1.08 (0.95–1.22) | 1.07 (0.94–1.21) | 3249 | 73 | 16,233 | 188 | 089 (0.68–1.17) | 0.91 (0.69–1.19) |
Progestogens alone | 4629 | 1035 | 23,178 | 1996 | 0.96 (0.89–1.04) | 0.97 (0.90–1.04) | 4635 | 148 | 23,178 | 279 | 0.99 (0.81–1.21) | 1.00 (0.82–1.22) |
Tibolone alone | 358 | 45 | 1793 | 14 | 0.90 (0.49–1.63) | 0.83 (0.45–1.53) | 355 | 14 | 1791 | 3 | 1.31 (0.38–4.58) | 1.44 (0.41–5.09) |